Curaleaf (OTCMKTS:CURLF) Shares Gap Down - Time to Sell?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $3.52, but opened at $3.28. Curaleaf shares last traded at $3.51, with a volume of 249,844 shares changing hands.Wall Street Analysts Forecast GrowthThe Cannabis Sector's Billion-Dollar Tax CutSeparately, Zacks Research raised Curaleaf from a "strong sell" rating to a "hold" rating in a research report on Thursday, January 1st. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Curaleaf currently has an average rating of "Buy".Read Our Latest Analysis on CuraleafCuraleaf Stock PerformanceThis 4/20, Wall Street Is Betting on More Than MarijuanaThe company has a current ratio of 1.52, a quick ratio of 0.76 and a debt-to-equity ratio of 1.14. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -11.45 and a beta of 0.77. The stock's 50 day moving average is $2.50 and its two-hundred day moving average is $2.59. Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 23.17%. The company had revenue of $333.07 million for the quarter, compared to analyst estimates of $328.70 million. Analysts anticipate that Curaleaf Holdings, Inc. will post -0.26 earnings per share for the current fiscal year. Curaleaf Company Profile (Get Free Report)Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company's vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements. Curaleaf's product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.See AlsoFive stocks we like better than CuraleafThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Curaleaf Right Now?Before you consider Curaleaf, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here